文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

脓毒症患者医疗费用与成本效益的时间趋势:日本全国医疗索赔数据库研究

Temporal trends of medical cost and cost-effectiveness in sepsis patients: a Japanese nationwide medical claims database.
PubMed 文献 · J Intensive Care · 2022-07-14
一句话结论日本2010–2017年全国索赔数据显示,脓毒症患者年总医疗费用从30.4亿美元升至43.8亿美元,但每住院费用下降(每年−1075美元,p<0.0001),每存活者有效成本显著下降(每年−1806美元,95%CI −2432至−1179,p=0.001)。

该研究为回顾性研究,利用日本2010–2017年全国医疗索赔数据库,纳入20岁以上、符合推定严重感染合并器官衰竭诊断的脓毒症患者共1,276,678例。主要终点为每年每存活者有效成本(总医疗费用除以存活人数)的年度趋势。结果显示年总医疗费用从2010年30.4亿美元逐渐增至2017年43.8亿美元,但每住院医疗费用下降(速率=−1075美元/年,p<0.0001);脓毒症患者生存率改善期间,每存活者有效成本显著下降(速率=−1806美元/年[95%CI −2432至−1179],p=0.001)。亚组分析中年龄、性别和感染部位亚组的每住院费用下降趋势一致;调整年龄、性别(男性)、慢性病数量、感染部位、ICU入住、手术和住院时长后,入院年份仍与医疗费用降低显著相关。结论为2010–2017年脓毒症患者年度成本效益改善。

要点

  • 年总医疗费用从2010年30.4亿美元增至2017年43.8亿美元,但每住院医疗费用下降(速率=−1075美元/年,p<0.0001)。
  • 每存活者有效成本显著下降(速率=−1806美元/年[95%CI −2432至−1179],p=0.001),同期生存率改善。
  • 年龄、性别和感染部位亚组的每住院费用下降趋势一致。
  • 调整年龄、性别(男性)、慢性病数量、感染部位、ICU入住、手术和住院时长后,入院年份仍与医疗费用降低显著相关。

适用人群与场景

  • 日本2010–2017年全国医疗索赔数据库中,20岁以上、符合推定严重感染合并器官衰竭诊断的脓毒症患者。

研究设计与关键结果

  • 研究类型为回顾性研究,使用日本全国医疗索赔数据库,纳入2010–2017年20岁以上脓毒症患者1,276,678例(来自50,490,128例成人索赔患者)。
  • 年总医疗费用从2010年30.4亿美元逐渐增至2017年43.8亿美元,但每住院医疗费用下降(速率=−1075美元/年,p<0.0001)。
  • 主要终点每存活者有效成本显著下降(速率=−1806美元/年[95%CI −2432至−1179],p=0.001),同期脓毒症患者生存率改善。
  • 亚组分析显示年龄、性别和感染部位的每住院医疗费用下降趋势一致。
  • 调整年龄、性别(男性)、慢性病数量、感染部位、ICU入住、手术和住院时长后,入院年份仍与医疗费用降低显著相关。

证据类型、等级与局限

  • 证据类型:回顾性研究,基于日本全国医疗索赔数据库。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is the leading cause of death worldwide. Although the mortality of sepsis patients has been decreasing over the past decade, the trend of medical costs and cost-effectiveness for sepsis treatment remains insufficiently determined.

METHODS: We conducted a retrospective study using the nationwide medical claims database of sepsis patients in Japan between 2010 and 2017. After selecting sepsis patients with a combined diagnosis of presumed serious infection and organ failure, patients over the age of 20 were included in this study. We investigated the annual trend of medical costs during the study period. The primary outcome was the annual trend of the effective cost per survivor, calculated from the gross medical cost and number of survivors per year. Subsequently, we performed subgroup and multiple regression analyses to evaluate the association between the annual trend and medical costs.

RESULTS: Among 50,490,128 adult patients with claims, a total of 1,276,678 patients with sepsis were selected from the database. Yearly gross medical costs to treat sepsis gradually increased over the decade from $3.04 billion in 2010 to $4.38 billion in 2017, whereas the total medical cost per hospitalization declined (rate = - $1075/year, p < 0.0001). While the survival rate of sepsis patients improved during the study period, the effective cost per survivor significantly decreased (rate = - $1806/year [95% CI - $2432 to - $1179], p = 0.001). In the subgroup analysis, the trend of decreasing medical cost per hospitalization remained consistent among the subpopulation of age, sex, and site of infection. After adjusting for age, sex (male), number of chronic diseases, site of infection, intensive care unit (ICU) admission, surgery, and length of hospital stay, the admission year was significantly associated with reduced medical costs.

CONCLUSIONS: We demonstrated an improvement in annual cost-effectiveness in patients with sepsis between 2010 and 2017. The annual trend of reduced costs was consistent after adjustment with the confounders altering hospital expenses.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Oami T, Imaeda T, Nakada TA, et al. Temporal trends of medical cost and cost-effectiveness in sepsis patients: a Japanese nationwide medical claims database. J Intensive Care. 2022. PMID: 35836301. doi:10.1186/s40560-022-00624-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。